Status:
COMPLETED
A Study of the Effect of Blinding in a Trial of Blood Filtration During Heart Surgery
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborating Sponsors:
Heart and Stroke Foundation of Ontario
Conditions:
Heart Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Cardiac surgery is a major consumer of blood products worldwide. The nature of the surgery when the heart-lung machine is used, is such that the patient's blood is significantly diluted by intravenous...
Detailed Description
The demographic of the cardiac surgery population has progressively changed such that there is a greater proportion of older patients and females who by virtue of their co-morbidities and smaller aver...
Eligibility Criteria
Inclusion
- Adult cardiac surgery patients with weight ≤ 65 kg or body surface area (BSA) \< 1.7 m2
Exclusion
- Emergency surgery
- Abciximab (Reopro™) use \< 7 days
- Inability to obtain consent
- Age \< 18 years
- Patients undergoing off-pump surgery
- Preoperative anemia
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00246779
Start Date
November 1 2005
End Date
June 1 2007
Last Update
September 27 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
2
University Hospital
London, Ontario, Canada, N6A 5A5
3
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
4
Royal Victoria Hospital
Montreal, Quebec, Canada, H3A 1A1